2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 309

Sub-Clinical Disease Activity in the Feet of Patients with Early Rheumatoid Arthritis: What Clinical Assessments Miss

Imaging of Rheumatic Diseases Poster I: MRI

9:00AM-11:00AM: Abstract Number: 707

Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 690

Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 573

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 166

Superior Sensitivity for Detection of Primary Antiphospholipid Syndrome By a 9-Test Panel in Patients with Deep Venous Thrombosis, Pulmonary Embolism, and Stroke or Transient Ischemic Attack

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 616

Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 66

Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 823

Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings

Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

9:00AM-11:00AM: Abstract Number: 179

Swimming Against the Stream- the Fishbowl Discussion Method As an Interactive Tool for Medical Conferences – Experiences from the 11. European Lupus Meeting

Education Poster

9:00AM-11:00AM: Abstract Number: 322

Swollen Joint Count Vs. RAPID3: Why a Discrepancy in Remission State?

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 368

Synovianalysis Using Leukocyte Esterase Reagent Strips

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 395

Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 32

T Cell-Intrinsic Nod2 Protects Against Th17-Mediated Autoimmune Arthritis in SKG Mice

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 147

T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 625

Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].